KR102080142B1 - 목표 분자에 결합력을 갖는 ｌ-형 핵산 및 이를 제조하는 방법 - Google Patents

목표 분자에 결합력을 갖는 ｌ-형 핵산 및 이를 제조하는 방법 Download PDF

Info

Publication number
KR102080142B1
KR102080142B1 KR1020197016125A KR20197016125A KR102080142B1 KR 102080142 B1 KR102080142 B1 KR 102080142B1 KR 1020197016125 A KR1020197016125 A KR 1020197016125A KR 20197016125 A KR20197016125 A KR 20197016125A KR 102080142 B1 KR102080142 B1 KR 102080142B1
Authority
KR
South Korea
Prior art keywords
nucleic acid
acid molecule
derivative
nucleotide
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016125A
Other languages
English (en)
Korean (ko)
Other versions
KR20190067260A (ko
Inventor
플로리안 자로스크
스벤 클루스만
사이먼 셀
웨너 펄스치크
크리스티안 마스크
악셀 바터
카이 호리그
Original Assignee
아프타리온 바이오테크 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2011/002068 external-priority patent/WO2011131371A1/en
Application filed by 아프타리온 바이오테크 아게 filed Critical 아프타리온 바이오테크 아게
Publication of KR20190067260A publication Critical patent/KR20190067260A/ko
Application granted granted Critical
Publication of KR102080142B1 publication Critical patent/KR102080142B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/13—Applications; Uses in screening processes in a process of directed evolution, e.g. SELEX, acquiring a new function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197016125A 2011-01-10 2012-01-10 목표 분자에 결합력을 갖는 ｌ-형 핵산 및 이를 제조하는 방법 Active KR102080142B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11000117.9 2011-01-10
EP11000117 2011-01-10
PCT/EP2011/002068 WO2011131371A1 (en) 2010-04-21 2011-04-21 Lipid binding nucleic acids
EPPCT/EP2011/002068 2011-04-21
EP11008467 2011-10-21
EP11008467.0 2011-10-21
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137017897A Division KR20140026357A (ko) 2011-01-10 2012-01-10 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법

Publications (2)

Publication Number Publication Date
KR20190067260A KR20190067260A (ko) 2019-06-14
KR102080142B1 true KR102080142B1 (ko) 2020-02-21

Family

ID=45464586

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197016125A Active KR102080142B1 (ko) 2011-01-10 2012-01-10 목표 분자에 결합력을 갖는 ｌ-형 핵산 및 이를 제조하는 방법
KR1020137017897A Ceased KR20140026357A (ko) 2011-01-10 2012-01-10 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137017897A Ceased KR20140026357A (ko) 2011-01-10 2012-01-10 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법

Country Status (8)

Country Link
US (2) US9976145B2 (https=)
EP (1) EP2663640B1 (https=)
JP (2) JP2014504865A (https=)
KR (2) KR102080142B1 (https=)
CN (1) CN103339258A (https=)
AU (1) AU2012206750A1 (https=)
CA (1) CA2824073A1 (https=)
WO (1) WO2012095303A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533098A (ja) * 2011-10-21 2014-12-11 ノクソン・ファルマ・アクチエンゲゼルシャフト グルカゴン結合核酸
KR102034203B1 (ko) * 2012-01-10 2019-10-18 아프타리온 바이오테크 아게 새로운 C5a 결합 핵산
BR112014016939A2 (pt) * 2012-01-10 2019-09-24 Noxxon Pharma Ag ácidos nucleicos que se ligam especificamente a cgrp
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
WO2019222340A1 (en) 2018-05-17 2019-11-21 The Procter & Gamble Company Systems and methods for hair coverage analysis
CN112771164B (zh) 2018-06-29 2026-03-27 宝洁公司 用于个人护理应用的适配体
CA3134968A1 (en) 2019-04-16 2020-10-22 Juan Esteban Velasquez Aptamers for odor control applications
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications
EP4306640A1 (en) 2022-06-21 2024-01-17 TME Pharma AG Method for treating a tumor in a subject
KR20250025627A (ko) 2022-06-21 2025-02-24 티엠이 파마 아게 대상체의 종양을 치료하는 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049828A1 (en) * 2003-11-10 2005-06-02 Noxxon Pharma Ag Nucleic acids specifically binding bioactive ghrelin

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
DE59708838D1 (de) 1996-08-30 2003-01-09 Jens Peter Fuerste Spiegelselektion und spiegelevolution von nucleinsäuren
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1264603B8 (en) * 2001-06-10 2010-03-03 Noxxon Pharma AG Use of L-polynucleotides for in vivo imaging
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ATE469164T1 (de) 2001-10-26 2010-06-15 Noxxon Pharma Ag Modifizierte l-nukleinsäure
WO2003070823A2 (en) 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
NZ542687A (en) 2003-04-13 2010-02-26 Enzon Pharmaceuticals Inc Polymeric oligonucleotide prodrugs
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
CA2555467C (en) 2004-02-09 2012-10-09 Noxxon Pharma Ag Process for the production of conjugates from polysaccharides and polynucleotides
CA2940803A1 (en) 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Prodrug linker
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
JP5107716B2 (ja) 2004-11-05 2012-12-26 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 分子治療用生分解性リンカー
US20090075342A1 (en) 2005-04-26 2009-03-19 Sharon Cload Metabolic profile directed aptamer medicinal chemistry
US20120101267A1 (en) 2005-10-07 2012-04-26 Alison Velyian Todd Multicomponent nucleic acid enzymes with cleavage, ligase or other activity and methods for their use
JP5665272B2 (ja) 2005-10-07 2015-02-04 スピーデクス ピーティーワイ リミテッド 多成分核酸酵素およびそれらの使用方法
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
US8962238B2 (en) 2007-04-05 2015-02-24 SpeedDx Pty Ltd Nucleic acid enzymes and complexes and methods for their use
WO2010014572A2 (en) * 2008-07-28 2010-02-04 Idera Pharmaceuticals, Inc. Modulation of toll-like receptor 9 expression by antisense oligonucleotides
EP2561079A1 (en) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049828A1 (en) * 2003-11-10 2005-06-02 Noxxon Pharma Ag Nucleic acids specifically binding bioactive ghrelin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of biological chemistry (2001) 276(38) 35320-35327.

Also Published As

Publication number Publication date
JP2017148055A (ja) 2017-08-31
EP2663640B1 (en) 2020-11-04
WO2012095303A1 (en) 2012-07-19
JP2014504865A (ja) 2014-02-27
US9976145B2 (en) 2018-05-22
KR20190067260A (ko) 2019-06-14
CA2824073A1 (en) 2012-07-19
KR20140026357A (ko) 2014-03-05
US20140350088A1 (en) 2014-11-27
AU2012206750A1 (en) 2013-07-18
US20190367921A1 (en) 2019-12-05
EP2663640A1 (en) 2013-11-20
CN103339258A (zh) 2013-10-02

Similar Documents

Publication Publication Date Title
KR102080142B1 (ko) 목표 분자에 결합력을 갖는 ｌ-형 핵산 및 이를 제조하는 방법
EP1737879B1 (en) Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
CN103946381B (zh) Ngf适体及其应用
AU2007276435C1 (en) SDF-I binding nucleic acids
EP2407558A1 (en) Methods for the detection of a single- or double-stranded nucleic acid molecule
US20060264369A1 (en) Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
JP2023068147A (ja) Ｅｐａｓ１関連疾患を治療するための有機組成物
CN101809154A (zh) C5a结合核酸
CN102686729A (zh) 用于治疗hsf1相关疾病的有机组合物
WO2013142735A1 (en) Targeting domain and related signal activated molecular delivery
JP2008512098A (ja) フォン・ビルブラント因子に対するアプタマー、および血栓性疾患の処置剤としてのその使用
US9163243B2 (en) Nucleic acids specifically binding CGRP
KR20140083039A (ko) 글루카곤 결합형 핵산
Cheng et al. Oligodeoxyribonucleotide length and sequence effects on intramolecular and intermolecular G-quartet formation
WO2005052121A2 (en) Multivalent aptamers
EP3065744B1 (en) A ccl2 antagonist for use in treating proteinuria
CN113383079A (zh) Cxcl8结合性核酸
HK1146296A (en) C5a binding nucleic acids

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7